WALTHAM, MA – Marketwired – Nov 26, 2014 – Fractyl Laboratories Inc., the company pioneering the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with type 2 diabetes, will participate in the Piper Jaffray 26th Annual Healthcare Conference taking place at The New York Palace Hotel in New York City.

Fractyl Co-founder and CEO, Harith Rajagopalan, M.D., Ph.D., is scheduled to present an overview of the company on Wednesday, December 3, 2014 at 1:30 p.m. Eastern Time.

About Fractyl

Fractyl’s mission is to set people free from the daily burdens of type 2 diabetes management, empower physicians with a safe and reliable therapeutic treatment option, and lower the tremendous human and financial costs of diabetic complications for patients, hospitals, and payers. New scientific insights highlight the role of intestinal hormones in contributing to insulin resistance. Fractyl has developed a device-based procedure to directly address this intestinal hormonal impairment with a same-day therapy. Fractyl is currently engaged in clinical trials designed to demonstrate that its procedure can dramatically improve glucose control and reduce the need for additional medications. More information is available at www.fractyl.com or www.twitter.com/FractylLabs.

Media Contact
Russell LaMontagne
russell@corinthgroup.com
Tel: 917-744-7957

We use cookies to improve your experience on the Fractyl website. By continuing to use our site you agree to our use of cookies.
Learn More.
CLOSE